AbstractA novel [32P]‐CP‐PLLA ([32P]‐chromic phosphate‐poly‐L‐lactic acid) microparticle was designed and evaluated for the treatment of pancreatic carcinoma. The microparticle was prepared from [32P] chromic phosphate and poly‐L‐lactic acid. Bioelimination, biodistribution, SPECT image, and therapeutic effect were studied in mice bearing human pancreatic tumor xenografts. [32P]chromic phosphate ([32P]‐CP) colloid at the same radioactivity dose was compared as the control. High radioactivity (>95%ID) of [32P]‐CP‐PLLA was retained at the tumor, and almost no radioactivity excretion (<1%ID) was observed in urine and feces for 14 days, while radioactivity of [32P]‐CP colloid, was distributed to the liver, spleen, and lung (varied individual), and the excretion increased over 5%ID. Compared with controls, reduced tumor volumes were seen in the [32P]‐CP‐PLLA microparticle treatment group (P<0.01). Dose dependence was seen histologically. [32P]‐CP‐PLLA microparticle retained high activity and long‐term residence in tumor. With minimal distribution to normal organs [32P]‐CP‐PLLA microparticle is superior to [32P]‐CP colloid and is more suitable for brachytherapy in solid tumor. Drug Dev Res 71:364–370, 2010. © 2010 Wiley‐Liss, Inc.

2010-04-01·Cancer Biotherapy and Radiopharmaceuticals4区 · 医学

Intratumoral Injection of³²P-Chromic Phosphate in the Treatment of Implanted Pancreatic Carcinoma

4区 · 医学

Article

作者: Jiang, Bo ; Wang, Yu ; Liu, Zhi-Yong ; Liu, Lu ; Gao, Wen ; Liu, Xin-Nong

AIMThe aim of this study was to observe the biological distribution and anticancer effect of (32)P-chromic phosphate colloid (Cr(32)PO(4), (32)P-CP) after intratumoral injection to Pc-3 human pancreatic carcinoma-bearing nude mice.METHODSEighty-four (84) BALB/c nude mice with transplanted tumor were allocated to 11 groups. Groups 1-5 (n = 6) were intratumorally injected with 14.8 MBq of (32)P-CP and sacrificed at 2, 24, 48, 72, and 168 hours, respectively. Groups 6-11 (n = 9) received injections of 3.7, 7.4, 14.8, 18.5, 29.6, and 0 MBq of (32)P-CP, respectively, and the tumor volume on body surface was measured daily. The animals (n = 6) were sacrificed at 14 days after administration. The dynamic distribution of radioactivity in body (percentage of injected dose per g), morphological changes, the tumor-inhibiting rate (TIR), proliferating index (PI), proliferating cell nuclear antigen (PCNA) tumor microvascular density (MVD), continuous counting of white blood cells (WBCs) and platelets (PLTs) in venous blood, body weight, and toxic reactions were observed.RESULTSThe injected (32)P-CP mainly accumulated in the tumor mass and was retained for a long time. The TIR of each dosage group in order was 21.68%, 39.73%, 50.43%, 71.18%, and 74.09% (F = 159.74; p < 0.001), PI was 70.85, 67.90, 46.70, 20.66, 10.75, and 90.11 (F = 509.54; p < 0.001), and MVD count was 39.19, 28.33, 17.45, 8.89, 8.10, and 64.80 (F = 643.26; p < 0.001), respectively. The data for WBC, PLT, and body weight observed for 28 days in the treatment groups did not indicate significant differences compared with those of the control group.CONCLUSIONSInterstitial injection of (32)P-CP seems to be a safe and effective interventional nuclide therapy for pancreatic carcinoma-bearing nude mice.

2009-06-01·Nuclear Medicine Communications4区 · 医学

Interstitial injection of 32P-chromic phosphate during lung cancer resection to treat occult lymphatic metastasis

4区 · 医学

Article

作者: Liu, Zhi-Yong ; Li, Chen ; Gao, Wen ; Li, Xu-Dong ; Liu, Lu

OBJECTIVEWe aimed to study the interstitial injection of (32)P-chromic phosphate colloids ((32)P-CP) during lung cancer resection to treat occult lymphatic metastasis, and to observe its medium-term and long-term effects.METHODSSeventy-three patients underwent surgery combined with injection of (32)P-CP with the dosage of 296-370 MBq/10 ml to the adipose and connective tissues neighboring pulmonary hilum, superior mediastinum, carina of trachea, and suspicious invaded pleura. Fifty-eight patients underwent only tumor resections served as control group. A monofactorial analysis by a chi test was conducted to determine the differences in positive rates of lymph nodes, the incidence of complications after the operation, the rate of supraclavicular lymph node metastasis, and the survival rate between the two groups. The survival curves were obtained using the Kaplan-Meier method and were compared by a log-rank test. The Cox's multivariate analysis was performed to identify the prognostic factors.RESULTSThere was no significant difference between lymph node-positive rates and the incidences of major complications (P>0.05). The rate of supraclavicular lymph node metastasis in surgery plus (32)P-CP group was prominently lower than that in the control group (P<0.05). Three-year and 5-year survival rates of the two groups showed significant difference (P<0.05). A Kaplan-Meier analysis revealed prominent statistical differences between the two groups (P<0.05). The Cox's multivariate analysis showed that the injection of (32)P-CP is one of the independent predictors of survival rates.CONCLUSIONInterstitial mediation with (32)P-CP during the resection of lung cancer is effective in inhibiting postoperative occult lymphatic metastasis, and showed satisfactory effects in improving patients' medium-term and long-term survival rates.

项与磷[32P]酸铬相关的新闻（医药）

2008-09-18

·BioSpace

Medwatch: Phosphocol P 32 - Risk of Leukemia Associated with Off-label Intra-Articular Use in Children

[Posted 09/18/2008] Covidien and Mallinckrodt Inc. informed healthcare professionals of important new safety information in prescribing Phosphocol P 32. Phosphocol P 32 is approved for the intracavitary instillation for the treatment of peritoneal or pleural effusions caused by metastatic disease. Phosphocol P 32 may increase the risk for leukemia in certain situations. Two children (ages 9 and 14) with hemophilia developed acute lymphocytic leukemia approximately 10 months after intra-articular injections of Phosphocol P 32 (0.6 and 1.5 mCi total dose). This drug is not indicated in the intra-articular treatment of hemarthroses. Additionally, post marketing experience identified radiation injury (necrosis and fibrosis) to the small bowel, cecum, and bladder following administration of P 32 into the peritoneal cavity. Healthcare professionals should refer to the product’s revised prescribing information for updated information regarding the appropriate use of Phosphocol P 32. Read more from the FDA .

放射疗法上市批准临床结果

100 项与磷[32P]酸铬相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2007	N/A	难治性头颈癌	14	Intralesional 32-P chromic phosphate	(廠構構範選簾鑰憲醖積) = 淵淵餘築鹽壓醖廠顧製窪鏇艱鬱艱鹹遞蓋願餘 (顧鹽壓鏇醖衊壓鹽衊齋 ) 更多	-	2007-06-20